Galapagos NV has initiated phase-I clinical development of its novel mechanism of action, first-in-class candidate drug GLPG0259 for rheumatoid arthritis (RA). GLPG0259 is the first small molecule from Galapagos’ target discovery platform to enter the clinic.
Arthritis Information
